Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential ...
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2
Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on ...
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 into a Phase 2 trial in Q3. Read more here.
Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...
bovnews2d
Vigil Neuroscience Inc (VIGL) Reported a – Operating Margin Last Year—What’s the Real Story?
William Blair has recently initiated Vigil Neuroscience Inc (VIGL) stock to Outperform rating, as announced on December 4, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had ...
Morningstar3d
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
BioSpace3d
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...